April 16, 2024

Navigating the Growing World of Litigation Funding and Contingent Risk Insurance

Subscribe to Our Newsletter

Newsletter


Kirstine Rogers

|

April 16, 2024

As 2024 is well underway and we enter the second quarter, the U.S. economic outlook remains mixed, with the economy showing signs of resilience and growth but also facing inflationary pressures, supply chain disruptions and geopolitical uncertainty.

Within this context, the U.S. legal market has fared relatively well, with rates increasing on average 6 percent in 2023 and demand strong in litigation, antitrust, M&A and restructuring. But declining realizations and productivity threaten law firm profitability. And clients, facing an uncertain economy, are putting pressure on firms to keep their budgets and legal costs in check. Indeed, the recent Thomson Reuters “Report on the State of the U.S. Legal Market” reports that clients are increasingly moving work to lower cost law firms or demanding capped or alternative fees from outside counsel.

As firms seek to enhance profitability while clients struggle to control legal costs, litigation finance can serve as a tool to offload legal spend, mitigate risk and increase revenues for both stakeholders. Indeed, as reported in the 2023 “Westfleet Insider 2023 Report on Litigation Finance,” more and more firms in the AmLaw 200 are seeing these benefits and utilizing funding, accounting for 35 percent of new deals in 2023.

Another tool that has emerged in recent years is contingent risk insurance. Over the past few years, contingent risk insurance has risen in prominence in the litigation finance world as an alternative or companion to traditional litigation finance.

This article provides a summary of the ways that clients and their counsel can use these tools to enhance revenue growth while controlling costs and mitigating the risks inherent in litigation.

About Litigation Finance

Litigation finance has become a permanent feature in the U.S. and Texas legal landscape. At its core, litigation finance is any transaction in which a litigation claim secures financing. Funds are provided on a non-recourse basis and the funder’s return depends on the outcome of the litigation. It comes in numerous forms and at any stage of litigation, from pre-filing to post judgment. The most common uses of funding are single-case funding, portfolio funding and claim monetization.

Single Case Funding

Funders often provide single case funding to clients for the fees and expenses associated with pursuing a litigation claim. For a high-stakes commercial claim, this can mean millions in legal fees and costs, including the costs of expert witnesses. Clients often either don’t have the capital to pay a full litigation budget or just as often, they have the capital but need to preserve it to reinvest in their business rather than in yearslong litigation.

Typically, single case funding involves a funder paying the full (or nearly full) amount of the cost budget and a substantial portion of the fee budget with the law firm taking the remaining portion “on risk” or on a partial contingency basis. Or sometimes law firms may elect to take a case on a contingency basis, but their clients seek funding for case expenses. The funder pays the fees and costs as they are incurred (often enhancing realizations for the firm) and receives a return out of the case proceeds upon resolution, but only if the case resolves successfully. If the case is unsuccessful, the funder does not recoup its principal or any return. Meanwhile, the law firm typically receives a portion of the upside or case proceeds from a successful outcome as well, but it will have received part of its hourly fee along the way regardless of case outcome. Most importantly, the client will have received the benefit of a full contingency arrangement with its preferred trial counsel, with little or no out of pocket spend. This structure helps the client reduce risk and litigation costs while pursuing a meritorious claim and helps the law firm represent its good client, mitigate risk and still share in the upside of a successful outcome, enhancing profitability.

Portfolio Funding

Portfolio funding involves financing multiple litigation or arbitration matters in a single transaction. The funding amount is typically still tied to the case budgets, like single-case funding. However, in portfolio funding, funders will invest in a group of cases at once, with any one of combination of those cases serving as collateral for the return. Just as with single-case funding, the investment is nonrecourse and the funded party — either a client or law firm — is not obligated to pay a funder’s return unless the portfolio yields positive case outcomes. Moreover, the law firm handling the cases recoups a portion of its fees as they are billed during the pendency of the lawsuits.

Funders invest in client-side or law firm-side portfolio transactions. For corporate clients, the underlying cases are typically a series of plaintiff-side affirmative claims that the company wishes to pursue, although the portfolio can include defense-side cases as well. For law firms, the portfolio will include cases that the firm is handling on a contingency bases for one or several different clients, with its anticipated fees from the cases serving as collateral for the investment. Such an arrangement allows the firm to offer its clients a full contingency arrangement, while mitigating that risk through a portfolio in which it recovers a portion of its hourly fees as they are incurred. As reported in the “Westfleet Insider,” portfolio transactions accounted for 66 percent of new commitments in 2023.

Claim Monetization

Clients and law firms increasingly are seeking to monetize both pending claims and post-trial judgments and awards. Claim monetization refers to an investor providing capital to a plaintiff in advance of the resolution of its claims — in essence turning a legal claim into a financial asset. Claim monetization accounted for 21 percent of capital commitments in 2023, up from 14 percent in 2022.

Insurance and its Interplay with Litigation Finance

Like litigation finance before it, contingent risk insurance has become a prominent feature in the litigation landscape. But, despite an offering of various insurance products, most practitioners know little about what it is or how it can be leveraged. 

Litigators are familiar with general liability insurance policies. Contingent risk insurance policies are something very different. They are bespoke, case-specific policies, tailored to the specific legal issues and facts of specific cases, lawyers, parties and risks involved. They are available to plaintiffs, defendants, their counsel and, as discussed further below, even their funders. These policies not only can provide an efficient mechanism to remove risk but increasingly have become a way to make capital more accessible to litigants and their counsel. 

Types of Contingent Risk Insurance

Although each insurance policy is tailored to the risk at hand, there are some basic policy structures that serve as building blocks to more complex policies.  These are useful in understanding how contingent risk insurance policies can be structured. They include: 

  • Judgment Preservation Insurance (JPI)  allows a plaintiff or counter-plaintiff to insure all or part of a damage award while an appeal is pending or, depending on the strength of the case, before judgment is even entered. This can be utilized in litigation and arbitration. 
  • Adverse Judgment Insurance (AJI)  is a form of insurance that guarantees a certain amount of coverage to a defendant in the event of a final, adverse judgment against it. A type of this policy is often used to facilitate the completion of M&A transactions when there is pending litigation against the seller and the buyer does not want to assume the risk of an adverse judgment. This type of policy basically ring-fences a certain legal exposure.
  • Contingent Fee Insurance  provides a company or law firm with downside protection to prevent a total loss of expenses or work in progress incurred in the prosecution of litigation by insuring some portion of the attorneys’ time and case costs.
  • Capital Protection Insurance  can be used to protect the investment capital used to fund a case or group of cases against an adverse ruling in the litigation.

Generally, there can be no loss under these policies unless and until the judgment or award is final or a case is fully resolved and there is no longer any chance of further appeal. If the insured party (or party aligned with the insured) does not prevail at the end of the day, then the policy covers the loss. As with funding, insurance policies can be written for a single case or a portfolio of cases. The premium charged for the policy is a percentage of the overall coverage and is dependent on the contours of the specific risk.  There is no standard market rate. 

How to Know When to Seek Out Funding or Insurance

Armed with the knowledge that both funding and insurance exist, what determines whether one (or both) are appropriate for a particular case or portfolio of cases? Although both funding and insurance seek to shift some of the risks inherent in litigation, they involve different considerations for both the funder and the funded and the insurer and the insured.

In turn, some cases may be more appropriate for funding than insurance or vice versa. And some cases may be appropriate for a combination of funding wrapped with insurance. Having a sense of the differences will help determine which path to pursue. 

For the client and counsel, the most prominent consideration is whether capital is needed immediately or whether they merely seek to lock-in the value of a case or the fees associated with it. If it is the former, funding may be more suitable; if it’s the latter, insurance may be worth considering. At the most basic level, funding is money-in, while insurance is money-out. The trade-off depends on which door one chooses. 

While traditional litigation funding is generally made on a nonrecourse basis, at no upfront cost to the client, insurance policies require that some, if not all, of a policy’s premium be paid to the insurer before coverage is bound. Without money in hand to pay the insurance premium, insurance may not be a viable consideration (unless, as discussed below, the client is able to obtain premium finance which allows the client to obtain a policy at little to no out-of-pocket expense).

In this regard, another key consideration is the overall cost of the capital.  When a case receives funding, the trade-off for the immediate access to funds on a nonrecourse basis is having to share a non-insignificant portion of case proceeds with the funder if the case is successful. This can be up to two to three times the amount of the funding given. Insurance coverage, on the other hand, usually does not involve any sharing of proceeds, or, if it does, the percentage of recovery shared is far less and only occurs in the event the litigation is successful. Instead, for a premium amounting to only a portion of the recovery, insurance preserves the status quo and gives the insured some certainty as to the economic impact of the litigation.   

Another consideration in choosing between funding and insurance is the role the funder or insurer may play in the overall litigation. Generally, litigation funders have no control over how the cases in which they invest are litigated. This is a key characteristic of the funding relationship. The funds are deployed on a nonrecourse basis. Even if the funder disagrees with a case strategy or settlement decision, the funds have been deployed for full use by the client and counsel and the funder has no say. Insurance policies, however, may contain exclusions for coverage such that certain strategic decisions may not be covered. In other words, while insurers also generally have no control over the litigation, certain strategic decisions by the client or counsel may result in there not being coverage in the event of a loss, but that is ultimately the insured’s choice and is determined by the express terms and exclusions of the policy. 

It is also important to note that not all cases or risks are appropriate for contingent risk insurance. First, cases that involve treble or punitive damages may be more attractive to a funder than an insurer. While a funder would share in the upside of such large damages, an insurer likely doesn’t want to share in the downside. Second, while a relatively new case that is in the prefiling or pretrial stage may make for a worthy investment for a funder due to the outsized potential reward, the legal and factual issues may not be sufficiently developed in order for an insurer to guarantee a particular result at the end of the case. Third, while collectability is generally inherent in the risk assumed by funders, insurers are generally not comfortable with collection risks and may exclude the collectability of a judgment from a policy’s terms. Finally, while case duration may be material to a funder’s investment decision since it affects overall returns, it may be likely less significant to an insurer and any durational risks can be built into a policy’s terms. These are just some of the many factors that funders, insurers, clients, lawyers and brokers may take into consideration in deciding how to proceed.

Emerging Issues: Blended Funding Families

One other alternative to consider is combining the funding and insurance.  This emerging solution is being seen more and more in the market and may increasingly become the norm. 

A capital protection insurance policy, for example, can be used as collateral with a third-party lender to create a more efficient cost of capital to the company or law firm utilizing the funding. A funder can obtain a judgment preservation policy seeking to insure recovery in a case or portfolio of cases. A litigant can obtain premium financing whereby the funder provides the capital to pay for the policy premiums and is repaid either through case proceeds or policy proceeds if there is a loss. There is great flexibility and creativity in this market, and it is only growing. 

At the end of the day, both funding and insurance are tools available to clients, law firms and funders to solve for the economic realities in the market. While there are many different considerations involved in deciding whether certain risks are more suitable for insurance or funding, the traits they share are the most critical to watch for. To be insured or funded, cases must be strong on the law and the facts; they must involve strong counsel in a solid jurisdiction; and the interests of all involved (client, counsel, and funder or insurer) must be aligned such that everyone is motivated and invested in a positive outcome for all. 

***

This article was originally published by The Texas Lawbook.

Certum Group Can Help

Get in touch to start discussing options.

Recent Content

By Ross Weiner July 23, 2026
Following up on the release of Certum Group’s Trade Secret Guide, the post below is the first in a series on recent appellate court trade secret decisions. These posts will examine groundbreaking decisions and their ramifications. Today’s post features the May 2026 decision in Versata Software, LLC v. Ford Motor Co., in which the Federal Circuit vacated and reversed key portions of the trial court’s damages rulings, holding that a plaintiff whose trade secret has been misappropriated can seek, as unjust enrichment damages, the value of the benefit that the defendant received, even if that amount is substantially more than the defendant would have paid for the trade secret. The case is now remanded for a new trial on trade secret misappropriation damages. Background In the early 2000s, Ford hired Versata Software, LLC (“Versata”) to develop computer software that would allow Ford to more efficiently enable vehicle configuration. Versata created two pieces of software: the Automotive Configuration Manager (“ACM”) and the Materials Cost Analytics (“MCA”). The deal was memorialized in a 2004 Master Subscription and Services Agreement (“MSSA”) as well as a separate but related agreement for Versata to provide additional support and services for the software. After 10 years, with the MSSA set to expire, the parties were unable to agree on an extension; instead, Ford “released its own manufacturing configuration software, called PDO, which Ford had developed while licensing software from Versata.”¹ Versata believed that Ford’s creation of PDO involved the misappropriation of its trade secrets and was done in violation of the parties’ agreements. After Ford filed a declaratory-judgment action against Versata,² Versata counterclaimed, alleging that Ford had misappropriated both ACM and MCA. During pre-trial proceedings, the district court severely curtailed Versata’s ability to establish damages by, among other things: • Excluding the testimony of Versata’s damages expert; • Limiting Versata’s trade secret damages to a “reasonable royalty model of damages that is based upon the parties’ relevant business history”³; and • Precluding Versata from seeking damages “based upon the alleged value of benefits obtained by Ford through its use of the relevant software.”⁴ Despite these draconian limitations, at an October 2022 jury trial, the jury found that Ford breached the MSSA and misappropriated three ACM trade secrets. Accordingly, the jury awarded Versata approximately $22 million for trade secret misappropriation (based on the parties’ licensing history) and approximately $82 million for breaching the MSSA.⁵ In post-trial briefing, Ford moved for JMOL on liability and damages. In response, the district court upheld the jury’s verdict that found Ford liable for trade secret misappropriation and breach of contract, but ultimately (i) reduced the trade secret damages to $0 (“the jury had no way to reliably determine how long it would have taken Ford to develop the three (out of four) trade secrets that it found to have been misappropriated”) and (ii) reduced the breach-of-contract damages from approximately $82 million to $3 (“because the jury had no way to calculate Versata’s claimed breach of contract damages with reasonable certainty”).⁶ In other words, the district court first precluded Versata from seeking significant unjust enrichment damages and then, when Versata prevailed on a more limited damages theory, the district court struck them. Versata timely appealed. The Federal Circuit Finds that DTSA Windfalls Are Just Fine In excluding Versata’s damages expert, the district court reasoned that his unjust enrichment model, based on the value to Ford of misusing the trade secrets, “would award Versata far more than the fair price it deemed Ford should pay in exchange for the software’s benefits” and “confer upon Versata a huge and undeserved windfall.”⁷ While this might have been a bug to the district court, to the Federal Circuit it was a feature of the Defend Trade Secrets Act (“DTSA”). The Federal Circuit, applying Sixth Circuit law, found that the district court was wrong to concern itself with a possible Versata “windfall” based on Ford’s significant misappropriation-driven savings. Indeed, the Federal Circuit noted that this category of damages is found directly in the DTSA’s text, which explicitly allows a court to award “damages for any unjust enrichment caused by the misappropriation of the trade secret that is not addressed in computing damages for actual loss.”⁸ The Federal Circuit found a 2008 Tenth Circuit Case, Russo v. Ballard Medical Products, particularly instructive.⁹ There, the court acknowledged that “although unjust enrichment damages ‘put [the plaintiff] in a much better position than if he had entered a licensing agreement … under Utah law, [defendant], as the party that acted wrongfully, must assume the risk it took by misappropriating rather than licensing [the trade secret].’”¹⁰ In other words, corporate actors should play by the rules; if not, they might learn that trade secret damages awards can dwarf the cost they could have paid. Because the district court’s decision to limit Versata’s damages theories to those based solely on the parties’ licensing history was error, the Federal Circuit found that Versata was effectively hamstrung at trial and during post-trial proceedings. Accordingly, the Federal Circuit partially vacated the trial court’s decision to zero out the trade secret damages award and remanded for a new trial on trade secret misappropriation damages.¹¹ Versata’s Contract Damages Were Proper and Should Be Reinstated Under Michigan law, damages for a breach of contract claim must be measured with “reasonable certainty,”¹² but “mathematical certainty” is not required.¹³ When a jury issues a contractual damages award, such award “must stand unless it is (1) beyond the range supportable by proof; or (2) so excessive as to shock the conscience; or (3) the result of a mistake.”¹⁴ The district court concluded that Versata’s approximately $82 million in contract damages could not stand because Versata had purportedly failed to present any evidence to aid the jury in this calculation.¹⁵ The Federal Circuit disagreed. Simply put, the Federal Circuit found that Versata met its burden. Specifically, at trial, Versata’s counsel presented three base damages amounts based on the parties’ licensing history: (1) $17 million (based on the amount Versata offered to license its software after the initial deal expired); (2) $14.95 million (the amount Ford paid Versata in the final year of the contract); and (3) $10.95 million (the base license fee under the MSSA, which amount did not include service and/or maintenance). Versata’s counsel told the jury to multiply any of those figures by 7.5 years, which represented “the period from the start of Ford’s misappropriation through trial.”¹⁶ The ultimate damages award of $82,260,000 reflected $10.97 million for each of the 7.5 years that Ford breached the MSSA. Because this damages figure was neither “beyond the range supported by proof,” nor “so excessive as to shock the conscience,” the Federal Circuit ordered it reinstated. Ramifications Versata’s win, led by Jeffrey Lamken of MoloLamken, is a shot in the arm for trade secret plaintiffs. A plaintiff’s ability to win substantial unjust enrichment damages, i.e., “damages for any unjust enrichment caused by the misappropriation of the trade secret that is not addressed in computing damages for actual loss,” is a driving factor in bringing a trade secret misappropriation claim. Limiting those damages to only “royalties-based damages models” would handcuff plaintiffs and turn trade secret damages into contract damages, in direct contravention of the DTSA. This decision should put corporate defendants on notice to think twice before stealing trade secrets. _ ¹ Op. at 3.  ² Ford initially sued Versata, seeking a declaratory judgment that it had not infringed upon Versata’s IP or misappropriated Versata’s trade secrets. In response, Versata counterclaimed, alleging trade secret misappropriation and breach of contract. ³ Op. at 4. ⁴ Id. ⁵ Id. at 5. ⁶ Id. at 5-6. ⁷ Op. at 4. ⁸ Op. at 7 (quoting 18 U.S.C. § 1836(b)(3)(B)(i)-(ii)). The court noted that the Michigan Unfair Trade Secrets Act (“MUTSA”) ⁹ 550 F.3d 1004, 1020 (10th Cir. 2008). The Russo court was interpreting the Utah Trade Secrets Act, “which includes the same language as the DTSA and MUTSA.” Id. at 1021. ¹⁰ Op. at 8-9. ¹¹ Op. at 11-12. ¹² Doe v. Henry Ford Health Sys.¸865 N.W.2d 915, 922 (Mich. App. 2014). ¹³ Chelsea Inv. Grp., LLC v. Chelsea, 792 N.W.2d 781, 792 (Mich. App. 2010). ¹⁴ Advance Sign Grp., LLC v. Optec Displays, Inc., 722 F.3d 778, 787 (6th Cir. 2013). ¹⁵ Op. at 13. ¹⁶ Id.
By Certum Team June 25, 2026
Chambers & Partners, a leading independent legal research company, has once again recognized Certum Group and William Marra as leaders in the U.S. litigation finance industry. For the second consecutive year, Certum Group earned a Band 2 ranking in Chambers’ intellectual property litigation funding category, placing the firm among a small group of U.S. funders recognized as leaders in patent and IP finance. William Marra, a director at Certum Group, was again ranked individually, recognized in Band 3 for his work in litigation support. Reviewers interviewed by Chambers spoke to the depth and discipline of the Certum team: Certum has “some of the smartest people in the industry working there. I really respect them: they are efficient, they know the market, make smart decisions and are very discerning.” Certum’s team has “highly sophisticated legal and practical minds with an excellent grasp of litigation financing and the ebbs and flows of the litigation space.” “Certum Group are super credible, wonderful people. They are all real lawyers and they all care about our business.” One reviewer described Will as “bar none the most sophisticated, practical, partner-oriented funding professional I have worked with in my years of litigation funding involvement,” noting that he “has helped me shape cases in ways that dramatically improved their litigation and settlement posture” and is “adept and intuitively knowing of how to get to the right solutions.” Others described Will as “an excellent partner” and as someone who “bases decisions on fundamentals and has strong strategic vision.”  Click here to see the complete rankings.
By Certum Team June 17, 2026
Certum Group is pleased to announce that Suneal Bedi has joined the company as our Scholar in Residence. Suneal Bedi is an Associate Professor of Business Law & Ethics and Jerome Bess Faculty Fellow at the Kelley School of Business at Indiana University. He is also the Research Director at the Institute for Corporate Governance and Ethics. He teaches classes in corporate law and business ethics. Professor Bedi has written extensively on litigation finance and intellectual property in various outlets including Vanderbilt Law Review, USC Law Review, Harvard Journal of Law & Technology, Alabama Law Review, and has a forthcoming piece which empirically measures the value of litigation finance in the NYU Law Review. His work broadly seeks to analyze the marketplace effects of litigation finance with an emphasis on discussing the investment vehicle outside of the courtroom. Professor Bedi also brings an expertise in business ethics to the field and recently co-authored a textbook on the same titled The Vision of the Firm. He has assisted in many cases as an expert witness testifying on both IP damages and the business ethics of litigation finance. “It’s important that academic researchers spend time in the field learning how things actually work and I’m grateful for this opportunity,” Bedi said. He has a B.A. in Economics from Swarthmore College, a J.D. from Harvard Law School, an M.S. in Marketing and joint PhD in Business Ethics and Marketing from The Wharton School at the University of Pennsylvania. Before academia, he worked as a private equity associate at the Boston office of Ropes & Gray, LLP. See Suneal's announcement on Bloomberg Law , and learn more about his role at Certum Group HERE .